|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis显示文摘 | Axel Dignass Rami Eliakim Fernando Magro Christian Maaser Yehuda Chowers Karel Geboes Gerassimos Mantzaris Walter Reinisch Jean-Frederic Colombel Severine Vermeire Simon Travis James O. Lindsay Gert Van Assche | 2012 | Journal of Crohn’s and Colitis2012，，10： | 12 |
| 2 | Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial显示文摘 | Geert D’Haens Filip Baert Gert van Assche Philip Caenepeel Philippe Vergauwe Hans Tuynman Martine De Vos Sander van Deventer Larry Stitt Allan Donner Severine Vermeire Frank J Van De Mierop Jean-Charles R Coche Janneke van der Woude Thomas Ochsenkühn Ad A | 2008 | The Lancet2008，，9613： | 5 |
| 3 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management显示文摘 | Axel Dignass James O. Lindsay Andreas Sturm Alastair Windsor Jean-Frederic Colombel Mathieu Allez Gert D’Haens André D’Hoore Gerassimos Mantzaris Gottfried Novacek Tom ?resland Walter Reinisch Miquel Sans Eduard Stange Severine Vermeire Simon Travis Gert | 2012 | Journal of Crohn’s and Colitis2012，，10： | 4 |
| 4 | Pharmacogenetics in inflammatory bowel disease显示文摘遗传药理学是在在药反应的可变性之间的协会的学习并且(或) 在基因的药毒性和多型性。科学的这个领域的目标是使药适应一个病人的特定的基因背景因此使他们更有效、安全。在这篇文章,我们在影响的基因描述变体在煽动性的肠疾病( IBD )的治疗使用的普通的药的功效或毒性, ulcerative ( UC ),和 Crohn 包括 sulfasalazine 和 mesalazine 是疾病( CD ), azathioprine ( AZA )和 6-mercaptopurine ( 6-MP ), methotrexate ( MTX ), glucocorticosteroids ( CS )和 infliximab 。而且, pharmacogenetic 研究的困难一般来说并且更明确地在 IBD 被描述。尽管遗传药理学是已经贡献了一些药的行动的内在的机制的更好的理解的一个有希望的领域,在 IBD 使用,翻译直到现在成每日的实践的唯一的发现是在 thiopurine S-methyltransferase (TPMT ) 基因多型性和 thiopurine 治疗的 hematological 毒性之间的关系。在未来,在很好描绘的耐心的队组织研究是必要的谁一致地被对待并且系统地评估了以便测定药反应更客观地。一个努力应该被作从为 pharmacogenetic 研究在适当知情同意以后在临床的药试用注册的所有病人收集 genomic DNA。 | Marie Pierik Paul Rutgeerts Robert Vlietinck Severine Vermeire | 2006 | World Journal of Gastroenterology2006，12，23： | 3 |
| 5 | Biological Therapies for Inflammatory Bowel Diseases显示文摘 | Paul Rutgeerts Severine Vermeire Gert Van Assche | 2009 | Gastroenterology2009，，4： | 3 |
| 6 | Role of genetics in prediction of disease course and response to therapy显示文摘The clinical course of Crohn's disease and ulcerative colitis is highly variable between patients,and this has therapeutic implications.A number of clinical features have been identified,which predict a mild or more severe outcome.However,several of these are subjective and/or not persistent over time.With the progress in genetics research in inflammatory bowel disease(IBD),genetic markers are increasingly being proposed to improve stratification of patients.Genetics have the major advantage of being stable over time and not prone to subjective interpretation.Nevertheless,none of the genetic variants associated with particular outcomes have shown sufficient sensitivity or specificity to have been implemented in daily management.Along the same line of thinking,pharmacogenetics or the study of association between variability in drug response and genetic variation has also received more attention as part of the endeavor for personalized medicine.The ultimate goal in this area of medicine is to adapt medication to a patient's specific genetic background and therefore improve on efficacy and safety rates.Although pharmacogenetic studies have been performed for all classes of drugs applied in IBD,few have generated consistent findings or have been replicated.The only genetic test approved for clinical practice is thiopurine S-methyltransferase testing prior to starting treatment with thiopurine analogues.The other reported associations have suffered from lack of confirmation or still need replication efforts.Nevertheless,the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed. | Severine Vermeire Gert Van Assche Paul Rutgeerts | 2010 | World Journal of Gastroenterology2010，16，21： | 3 |
| 7 | 制浆黑液成分对有机硅消泡剂效果的影响显示文摘运用黑液模型系统的实验设计(DOE)研究分析了黑液成分对有机硅消泡剂效果的影响。研究发现,树脂酸或木素的浓度变化对实验结果无任何影响,因此,将脂肪酸和中性成分列为主要影响因素。3种有机硅消泡剂的消泡性和持久性随脂肪酸含量的增加而降低。中性成分含量增加有助于提高消泡剂的性能。正如实验所预期的,每种消泡剂的性能变化曲线各不相同。 | Sung-Hsuen Chao Laurent Vermeire Torolf Laxen | 2010 | 国际造纸2010，29，4： | 3 |
| 8 | Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease显示文摘Anti-tumour necrosis factor α(anti-TNFα) therapy is an established treatment in inflammatory bowel disease.However, this treatment is associated with high costs and the possibility of severe adverse events representing a true challenge for patients, clinicians and health care systems.Consequently, a crucial question is raised namely if therapy can be stopped once remission is achieved and if so, how and in whom.Additionally, in a real-life clinical setting, discontinuation may also be considered for other reasons such as the patient's preference, pregnancy, social reasons as moving to countries or continents with less access, or different local policy or reimbursement.In contrast to initiation of anti-TNFα therapy guidelines regarding stopping of this treatment are missing.As a result, the decision of discontinuation is still a challenging aspect in the use of anti-TNFα therapy.Currently this is typically based on an estimated, case-by-case, benefit-risk ratio.This editorial is intended to provide an overview of recent data on this topic and shed light on the proposed drug withdrawal strategies. | Konstantinos Papamichael Severine Vermeire | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 9 | Genetic Risk Profiling and Prediction of Disease Course in Crohn’s Disease Patients显示文摘 | Liesbet Henckaerts Kristel Van Steen Isabel Verstreken Isabelle Cleynen Andre Franke Stefan Schreiber Paul Rutgeerts Séverine Vermeire | 2009 | Clinical Gastroenterology and Hepatology2009，，9： | 2 |
| 10 | Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: A randomized, double-blind, placebo-controlled trial显示文摘 | Paul Rutgeerts Gert van Assche Séverine Vermeire Geert D’Haens Filip Baert Maja Noman Isolde Aerden Gert de Hertogh Karel Geboes Martin Hiele Andre D’Hoore Freddy Penninckx | 2005 | Gastroenterology2005，，4： | 2 |
| 11 | Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn’s Disease显示文摘 | Matthias Jürgens Jestinah M. Mahachie John Isabelle Cleynen Fabian Schnitzler Herma Fidder Wouter van Moerkercke Vera Ballet Maja Noman Ilse Hoffman Gert van Assche Paul J. Rutgeerts Kristel van Steen Severine Vermeire | 2011 | Clinical Gastroenterology and Hepatology2011，，5： | 2 |
| 12 | Classification of inflammatory bowel disease: the old and the new显示文摘 | Severine Vermeire Gert Van Assche Paul Rutgeerts | 2012 | Current Opinion in Gastroenterology2012，，4： | 2 |
| 13 | Sa1922 Pilot Study on the Safety and Efficacy of Faecal Microbiota Transplantation in Refractory Crohn’s Disease显示文摘 | Severine Vermeire Marie Joossens Kristin Verbeke Falk Hildebrand Kathleen Machiels Karolien Van den Broeck Gert Van Assche Paul J. Rutgeerts Jeroen Raes | 2012 | Gastroenterology2012，，5： | 2 |
| 14 | Review article: anti‐adhesion therapies for inflammatory bowel disease显示文摘 | T. Lobatón S. Vermeire G. Assche P. Rutgeerts | 2014 | Aliment Pharmacol Ther2014，，6： | 2 |
| 15 | Structure-borne sound transmission between thin orthotropic plates: analytical solutions显示文摘 | Bosmans I Mees P Vermeir G | 1996 | Journal of Sound and Vibration1996，191，1： | 1 |
| 16 | Patient adherence to treatment: Three decades of research (A comprehensive review) 显示文摘 | Vermeire E Heamshaw H Van Royen P | 2001 | J Clini Pharm Ther2001，26，5： | 1 |
| 17 | The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications 显示文摘 | Satsangi J Silverberg MS Vermeire S | 2006 | Gut2006，55，6： | 1 |
| 18 | Targeting TNF -α for the treatment of inflammatory bowel disease 显示文摘 | Billiet T Rutgeerts P Vermeire S | 2014 | Expert Opin Biol Ther2014，14，1： | 1 |
| 19 | NOD2/CARD15 does not influence response to Infliximab in Crohn' s disease显示文摘 | Vermeire S Louis E Rutgeerts P | 2002 | Gastroenterology2002，123，： | 1 |
| 20 | Deficient host-bacteria interactions in inflammatory bowel dis- ease? The toll-like receptor (TLR)-4 Asp299gly poly- morphism is associated with Crohn's disease and ulcera- tive colitis显示文摘 | Franchimont D Vermeire S EI H | 2004 | Gut2004，53，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员